Reprieve Cardiovascular
Led by a seasoned management team with extensive experience in the medical device industry.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | $61.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Reprieve Cardiovascular is a medical device company that develops and commercializes therapies for fluid management in patients suffering from acute decompensated heart failure (ADHF).
The company's core offering is a personalized decongestion management system that automates the management of a patient's fluid levels. This system is designed to enable clinicians to remove excess fluid from patients with ADHF safely and effectively.
Reprieve Cardiovascular operates in the cardiovascular medical device market, targeting a patient population of over 25 million individuals with heart failure globally. The company's business model is centered on the development and sale of its proprietary medical devices to hospitals and other healthcare facilities that treat acute heart failure.
Keywords: medical devices, acute decompensated heart failure, fluid management, cardiovascular, decongestion, therapies, healthcare, life sciences, medical equipment, healthtech